Comparison of efficacy and influential factors between tislelizumab and sintilimab in the treatment of advanced NSCLC
- VernacularTitle:替雷利珠单抗与信迪利单抗治疗晚期NSCLC的效果比较及影响因素分析
- Author:
Yan PAN
1
;
Shengxi YANG
2
;
Jiaxin LIU
3
;
Haoyuan QIAN
3
;
Wenlian TU
4
Author Information
1. Dept. of Pharmacy，the First People’s Hospital of Yunnan Province/Kunhua Hospital Affiliated to Kunming University of Science and Technology，Kunming 650032，China;School of Pharmacy，Dali University，Yunnan Dali 671000，China
2. School of Pharmacy，Dali University，Yunnan Dali 671000，China
3. School of Pharmacy，Kunming Medical University，Kunming 650500，China
4. Dept. of Pharmacy，the First People’s Hospital of Yunnan Province/Kunhua Hospital Affiliated to Kunming University of Science and Technology，Kunming 650032，China
- Publication Type:Journal Article
- Keywords:
tislelizumab;
sintilimab;
non-small cell lung cancer;
clinical efficacy;
safety;
influential factors
- From:
China Pharmacy
2025;36(24):3096-3101
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the efficacy and safety of chemotherapy combined with tislelizumab or sintilimab in patients with advanced non-small cell lung cancer （NSCLC）， and to analyze the influential factors of prognostic. METHODS A retrospective study was conducted on 163 patients with advanced NSCLC who received chemotherapy combined with tislelizumab or sintilimab at the First People’s Hospital of Yunnan Province from September 1， 2021 to November 30， 2024. Among them， there were 90 patients in the tislelizumab group and 73 patients in the sintilimab group. The objective response rate （ORR）， disease control rate （DCR）， progression free survival （PFS）， and overall survival （OS） of two groups were observed， and the occurrence of adverse drug reactions in patients was evaluated. Kaplan-Meier method was used to plot PFS and OS survival curves， Log-rank test was applied for univariate analysis， and Cox regression model was used to evaluate the independent prognostic factors of PFS and OS. RESULTS The median PFS of patients in the tislelizumab group and the sintilimab group were 14.14 months （95%CI of 10.95-17.33） and 10.95 months （95%CI of 8.75-13.15）， respectively. The median OS was 25.89 months （95%CI of 22.67-29.11） and 24.25 months （95%CI of 19.34-29.16）， with ORR of 45.56% and 49.32%， DCR of 94.44% and 90.41%， and the incidence of adverse drug reactions of 84.44% and 79.45%， respectively， the differences were not statistically significant （P＞0.05）. Age ≥60 years （HR＝1.542， 95%CI of 1.044-2.278， P＝0.029） and systemic immune inflammatory nutritional index （SIINI）＞ 116.58 （HR＝1.541， 95%CI of 1.058-2.245， P＝0.024） were risk factors for PFS in NSCLC patients receiving immune checkpoint inhibitor therapy； the use of antibiotics may affect the overall survival of patients （P＝0.001）. CONCLUSIONS The efficacy and safety of chemotherapy combined with tislelizumab or sintilimab for advanced NSCLC are comparable； age≥60 years and SIINI ＞116.58 are risk factors for PFS in NSCLC patients， and the use of antibiotics may affect the patients’ OS.
